Results 201 to 210 of about 1,032,308 (279)

Neuropathic Pain: From Mechanisms to Therapeutic Interventions

MedComm, Volume 7, Issue 10, October 2026.
Neuropathic pain arises from peripheral nerve injury, central sensitization, neurotransmitter imbalance, neuroimmune activation, and maladaptive circuit remodeling. Clinical phenotyping and multimodal imaging can identify dominant peripheral and central mechanisms.
Yaling Dai, Mengquan Tan, Man Yuan, Huixian Zhou, Qin Xie, Jiling Zeng, Yixin Yang, Xinran He, Siyuan Song   +8 more
wiley   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well-documented intoxication cases and basic pharmacological data. [PDF]

Addiction
Sommer MJ, Grafinger KE, Hermanns-Clausen M, Auwärter V.   +3 more
europepmc   +1 more source

β‐Caryophyllene Mitigates Thioacetamide‐Induced Liver Fibrosis Through CB2‐Mediated Suppression of Necroptosis: A Therapeutic Investigation

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
β‐Caryophyllene is a multifunctional sesquiterpene with significant therapeutic potential. Our findings demonstrate that β‐caryophyllene exerts broad hepatoprotective effects through the activation of cannabinoid type 2 (CB2) receptors. These effects include suppression of oxidative stress–induced injury, attenuation of inflammatory responses ...
Lujain Bader Eddin, Seenipandi Arunachalam, Loay Lubbad, Fayez T. Hammad, Ernest Adeghate, Sandeep Subramanya, Shreesh Ojha   +6 more
wiley   +1 more source

Ocular effects of synthetic cannabinoids: a case-control study. [PDF]

Eye (Lond)
Kunduracı MS, Kırık F, Onur IU, Onur OS, Karsidag C, Yigit FU, Erkiran M.   +6 more
europepmc   +1 more source

(+)‐Trans‐Cannabidiol Is an Agonist at Human CB2 Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT (−)‐trans‐Cannabidiol ((−)‐CBD) is a principal phytocannabinoid from Cannabis sativa. (−)‐CBD has complex pharmacology but is a relatively weak inhibitor of CB1 and CB2 receptor signaling. Cannabidiol has two chiral centres and thus four stereoisomers.
Pedro Bans Burtchaell, Marina Junqueira Santiago, Chenxi Wang, Mehdi Hagdoost, Evie J. M. Clay, Dani Mohnot, Mark Connor   +6 more
wiley   +1 more source

Revealing the therapeutic potential of synthetic cannabinoids: a systematic review of cannabinoid receptor binding dynamics and their implications for cancer therapy. [PDF]

J Cannabis Res
Alghamdi SS, Albahlal HN, Aloumi DE, Bin Saqyah S, Alsubait A, Alamre J, Alrashed M, Alsuhabeny N, Mohammed AE.   +8 more
europepmc   +1 more source

Therapeutic intervention strategies in frontotemporal dementia: drug development pipeline

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 4, October/December 2026.
Abstract Frontotemporal dementia (FTD) is the second most common cause of early‐onset dementia after Alzheimer's disease, characterized by substantial genetic, clinical, and pathological heterogeneity. Despite progress in understanding its pathophysiology, no disease‐targeted therapies (DTTs) have been approved to date.
Federica Perrone, Nicoletta Locuratolo, Elena Carbone, Marisa Cappella, Roberto Rivabene, Elisa Fabrizi, Giuseppina Talarico, Nicola Vanacore, Eleonora Lacorte, Paola Piscopo   +9 more
wiley   +1 more source

[Determination of 65 synthetic cannabinoids in whole blood by QuEChERS-ultra performance liquid chromatography- mass spectrometry]. [PDF]

Se Pu
Xi Z, Ye Y, Li SP, Kang J, Liu WQ, Zhang J, Li DX.   +6 more
europepmc   +1 more source